Colorectal Cancer

Investigators found that less than a quarter of study participants with colorectal cancer were taking their medications as prescribed, suggesting that many could benefit from improved adherence.

The results of the new study were presented during the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.

FDA has granted Fast Track designation to Cardiff Oncology’s onvansertib, an oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor, for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer.

New treatments with biological agents and vaccines are creating a pathway for patients with metastatic CRC.

Pharmacists are a rich resource, not only in the management of colorectal cancer, but in every aspect of health care.

The FDA has approved encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation after prior therapy.

Moderate physical activity may improve progression-free survival and reduce treatment-related adverse effects in patients undergoing chemotherapy for advanced colorectal cancer.

Cancers of the lung, breast, prostate, and colon are most common in adults aged 85 years and older.

Colon cancer may spread to other parts of the body before original tumors are clinically detectable.